newsfilter
← Latest News
Business Wire·

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (NASDAQ:VALN, PARIS:VLA) to supply drug substance for an